Freeborn Rwere

Freeborn Rwere

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Freeborn Rwere has a total of 75 co-authors. Here are the top co-authors by number of shared publications:

  • Eric Richard Gross

    Department of Anesthesiology, Perioperative and Pain Medicine, School of Medicine, Stanford University, Stanford, CA, USA

    6 shared publications
  • Emily Manzombe

    Department of Chemistry, School of Natural Sciences and Mathematics, Chinhoyi University of Technology, Chinhoyi, Zimbabwe

    4 shared publications
  • Che-Hong Chen

    Department of Chemical and Systems Biology, Stanford University School of Medicine, Stanford, CA 94305, USA

    3 shared publications
  • Brilliant Nyathi

    Department of Chemistry, School of Natural Sciences and Mathematics, Chinhoyi University of Technology, Chinhoyi, Zimbabwe

    2 shared publications
  • Chido Venissa P Mudawarima

    Department of Chemistry, School of Natural Sciences and Mathematics, Chinhoyi University of Technology, Chinhoyi, Zimbabwe

    2 shared publications
  • Cleopas Mureya

    2 shared publications

Latest Publications

  • The JPET Editorial Fellowship: Opening the Blinds to the Peer Review and Editorial Process

    by Mayur K. Ladumor, Catharine A. Mielnik, Cristina D. Peterson, Freeborn Rwere, Eric R. Gross

  • Open Access

    Characterization of novel genetic mutations in aldehyde dehydrogenase 2 that cause alcohol flushing in humans

    by Freeborn Rwere, Rafaela Cr. Hell, Xuan Yu, Eric R. Gross

    ID 20893 Poster Board 253 Consuming alcohol can increase the risk of cancers including those of the head, neck, esophagus, bowel, breast, and liver. This cancer risk after alcohol consumption is increased several-fold for approximately 560 million East-Asian people who carry ALDH2*2 (rs671, E504K) variant in aldehyde dehydrogenase 2 (ALDH2), that limits the metabolism of the alcohol break-down product acetaldehyde. This ALDH2*2 variant is associated with the alcohol flushing syndrome and tachycardia. Whether other missense mutations in the ALDH2 gene exists that causes alcohol flushing and tachycardia remains poorly understood. Here we hypothesized other inactive ALDH2 missense mutations exists that cause acetaldehyde accumulation and alcohol flushing syndrome in humans. After IRB approval, we used selective ion flow mass spectrometry to quantify acetaldehyde levels for wild-type ALDH2, ALDH2*2, and other ALDH2 missense variants in humans after an alcohol challenge. In addition, we evaluated the activity of these proteins in vitro, and in 3T3 transiently transfected cells. Statistical analysis was performed by ANOVA and Tukey’s post hoc with significance set at prs671 (E504K) and two novel mutations, rs747096195 (R101G), and rs190764869 (R114W). After subjecting volunteers to an alcohol challenge (0.25g/kg), rs747096195 (R101G) and rs190764869 (R114W) cause facial flushing and 2-fold higher acetaldehyde accumulation, while rs671 causes 9-fold higher acetaldehyde accumulation relative to humans with wild type ALDH2. Further, heart rate changes after alcohol consumption correlate with inefficient acetaldehyde metabolism (r=0.90, 95% confidence 0.78-0.95, n=26, prs747096195 (R101G), rs190764869 (R114W), and rs671 (E504K) genetic variants in ALDH2 result in less efficient acetaldehyde metabolism relative to wild type ALDH2. Cellular reactive oxygen species (ROS) of the wild-type and mutant variants significantly increased by 2-3-fold for cells treated with ethanol compared to untreated cells. Together, we identified genetic variants in the ALDH2 enzyme besides rs671 that cause inefficient acetaldehyde metabolism and developed a method to non-invasively phenotype differences in acetaldehyde metabolism after an alcohol challenge in humans. This is an important step for developing precision medicine strategies to provide individualized recommendations regarding alcohol use by factoring in how genetics when coupled with phenotype may ultimately influence cancer risk from consuming alcohol. This work was supported by GM119522 (ERG).

  • Inhibitory and in silico molecular docking of Xeroderris stuhlmannii (Taub.) Mendonca & E.P. Sousa phytochemical compounds on human α-glucosidases

    by Brilliant Nyathi, Jonathan Tatenda Bvunzawabaya, Chido Venissa P Mudawarima, Emily Manzombe, Kudakwashe Tsotsoro, Major Allen Selemani, Gadzikano Munyuki, Freeborn Rwere


  • Open Access

    A human TRPV1 genetic variant within the channel gating domain regulates pain sensitivity in rodents

    by Shufang He, Vanessa O. Zambelli, Pritam Sinharoy, Laura Brabenec, Yang Bian, Freeborn Rwere, Rafaela C.R. Hell, Beatriz Stein Neto, Barbara Hung, Xuan Yu, et al.

    Pain signals are relayed to the brain via a nociceptive system, and in rare cases, this nociceptive system contains genetic variants that can limit the pain response. Here, we questioned whether a human transient receptor potential vanilloid 1 (TRPV1) missense variant causes a resistance to noxious stimuli and, further, whether we could target this region with a cell-permeable peptide as a pain therapeutic. Initially using a computational approach, we identified a human K710N TRPV1 missense variant in an otherwise highly conserved region of mammalian TRPV1. After generating a TRPV1K710N-knockin mouse using CRISPR/Cas9, we discovered that the K710N variant reduced capsaicin-induced calcium influx in dorsal root ganglion neurons. The TRPV1K710N rodents also had less acute behavioral responses to noxious chemical stimuli and less hypersensitivity to nerve injury, while their response to noxious heat remained intact. Furthermore, blocking this K710 region in WT rodents using a cell-penetrating peptide limited acute behavioral responses to noxious stimuli and returned pain hypersensitivity induced by nerve injury to baseline levels. These findings identify K710 TRPV1 as a discrete site that is crucial for the control of nociception and provide insights into how to leverage rare genetic variants in humans to uncover fresh strategies for developing pain therapeutics.


  • SGLT2 inhibitor ameliorates endothelial dysfunction associated with the commonALDH2alcohol flushing variant

    by Hongchao Guo, Xuan Yu, Yu Liu, David T. Paik, Johanne Marie Justesen, Mark Chandy, James W. S. Jahng, Tiejun Zhang, Weijun Wu, Freeborn Rwere, et al.

    The common aldehyde dehydrogenase 2 (ALDH2) alcohol flushing variant known asALDH2*2affects ∼8% of the world’s population. Even in heterozygous carriers, this missense variant leads to a severe loss of ALDH2 enzymatic activity and has been linked to an increased risk of coronary artery disease (CAD). Endothelial cell (EC) dysfunction plays a determining role in all stages of CAD pathogenesis, including early-onset CAD. However, the contribution ofALDH2*2to EC dysfunction and its relation to CAD are not fully understood. In a large genome-wide association study (GWAS) from Biobank Japan,ALDH2*2was found to be one of the strongest single-nucleotide polymorphisms associated with CAD. Clinical assessment of endothelial function showed that human participants carryingALDH2*2exhibited impaired vasodilation after light alcohol drinking. Using human induced pluripotent stem cell–derived ECs (iPSC-ECs) and CRISPR-Cas9–correctedALDH2*2iPSC-ECs, we modeledALDH2*2-induced EC dysfunction in vitro, demonstrating an increase in oxidative stress and inflammatory markers and a decrease in nitric oxide (NO) production and tube formation capacity, which was further exacerbated by ethanol exposure. We subsequently found that sodium-glucose cotransporter 2 inhibitors (SGLT2i) such as empagliflozin mitigatedALDH2*2-associated EC dysfunction. Studies inALDH2*2knock-in mice further demonstrated that empagliflozin attenuatedALDH2*2-mediated vascular dysfunction in vivo. Mechanistically, empagliflozin inhibited Na+/H+-exchanger 1 (NHE-1) and activated AKT kinase and endothelial NO synthase (eNOS) pathways to ameliorateALDH2*2-induced EC dysfunction. Together, our results suggest thatALDH2*2induces EC dysfunction and that SGLT2i may potentially be used as a preventative measure against CAD forALDH2*2carriers.


  • Open Access

    Inhibitory and in silico molecular docking of Xeroderris stuhlmannii (Taub.) Mendonca & E.P. Sousa phytochemical compounds on human α-glucosidases

    by Brilliant Nyathi, Jonathan Tatenda Bvunzawabaya, Chido Venissa P Mudawarima, Emily Manzombe, Kudakwashe Tsotsoro, Major Allen Selemani, Gadzikano Munyuki, Freeborn Rwere

    Ethnopharmacological relevance: Herbal traditional medicine is used by millions of people in Africa for treatment of ailments such as diabetes mellitus, stomach disorders and respiratory diseases. Xeroderris stuhlmannii (Taub. ) Mendonca & E.P. Sousa ( X. stuhlmannii (Taub.)) is a medicinal plant used traditionally in Zimbabwe to treat type 2 diabetes mellitus (T2DM) and its complications. However, there is no scientific evidence to support its inhibitory effect against digestive enzymes (α-glucosidases) that are linked to high blood sugar in humans. Aim of the study: : This work aims to investigate whether bioactive phytochemicals of crude X. stuhlmannii (Taub.) can scavenge free radicals and inhibit α-glucosidases in order to reduce blood sugar in humans. Materials and methods: Here we examined the free radical scavenging potential of crude aqueous, ethyl acetate and methanolic extracts of X. stuhlmannii (Taub.) using the diphenyl-2-picrylhydrazyl assay in vitro . Furthermore, we carried out in vitro inhibition of α-glucosidases (α-amylase and α-glucosidase) by the crude extracts using chromogenic 3,5-dinitrosalicylic acid and p-nitrophenyl-α-D-glucopyranoside substrates. We also used molecular docking approaches (Autodock Vina) to screen for bioactive phytochemical compounds targeting the digestive enzymes. Results: Our results showed that phytochemicals in X. stuhlmannii (Taub.) aqueous, ethyl acetate and methanolic extracts scavenged free radicals with IC 50 values ranging from 0.002-0.013 μg/mL. Furthermore, crude aqueous, ethyl acetate and methanolic extracts significantly inhibited α-amylase and α-glucosidase with IC 50 values of 10.5-29.5 μg/mL (versus 54.1±0.7 μg/mL for acarbose) and 8.8-49.5 μg/mL (versus 161.4±1.8 μg/mL for acarbose), respectively. In silico molecular docking findings and pharmacokinetic predictions showed that myricetin is likely a novel plant-derived α-glucosidase inhibitor. Conclusion: Collectively, our findings suggest pharmacological targeting of digestive enzymes by X. stuhlmannii (Taub.) crude extracts may reduce blood sugar in humans with T2DM via inhibition of α-glucosidases.


  • Open Access

    Natural products for the treatment and management of diabetes mellitus in Zimbabwe-a review

    by Remigio Usai, Stephen Majoni, Freeborn Rwere

    Use of medicinal plants and herbs in the treatment and management of diseases, including diabetes mellitus and its complications remains an integral part of African tradition. In Zimbabwe, nearly one million people are living with diabetes mellitus. The prevalence of diabetes mellitus in Zimbabwe is increasing every year due to lifestyle changes, and has accelerated the use of traditional medicines for its treatment and management in urban areas. In addition, the high cost of modern medicine has led many people in rural parts of Zimbabwe to rely on herbal plant medicine for the treatment of diabetes mellitus and its complications. This review highlights a number of studies carried out to evaluate the antidiabetic properties of indigenous plants found in Zimbabwe with the goal of treating diabetes mellitus. Further, we discuss the mechanism of action of various plant extracts in the treatment and management of diabetes mellitus. Together, this review article can open pathways leading to discovery of new plant derived medicines and regularization of use of crude plant remedies to treat diabetes mellitus by the Zimbabwean government and others across Africa.


  • Open Access

    Aldehydes, Aldehyde Metabolism, and the ALDH2 Consortium

    by Freeborn Rwere, Xuan Yu, Che-Hong Chen, Eric R. Gross

    The discovery of aldehydes dates back to 1774 when Carl Wilhelm Scheele synthesized acetaldehyde


  • Open Access

    A new preconcentration technique for the determination of PGMs and gold by fire assay and ICP-OES

    by A. Masasire, F. Rwere, P. Dzomba, M. Mupa

    Accurate determination of platinum group metals (PGMs) and gold (Au) has always proven to be a difficult task, due to their low concentrations in platiniferous ores. The most common preconcentration technique used in analysis of these metals is fire assay with a flux containing nickel or lead. This technique can be improved by using co-collectors. Here we hypothesise that Fe, Co, and Cu can be used as co-collectors to enhance separation and preconcentration of PMGs and gold by fire assay. To test this hypothesis, geological exploration samples from Siyanda Union Mine (Northam, South Africa) were analysed by an inductively coupled plasma-optical emission spectrometer (ICP-OES) for PGMs (Pt, Pd, and Rh) and Au. A control sample (certified reference material AMIS 0426) was also analysed by the same technique. The PGM and Au recoveries from the control sample ranged from 83% to 105% for all three co-collectors, with relative standard deviations less than 10% for the control sample and 7% for the geological samples. The PGM and Au recoveries by Fe and Co co-collectors were modestly higher than that of the Cu-collector. These results indicate that Fe and Co are better co-collectors than Cu, presumably due to the loss of analyte when using Cu. Taken together, Fe and Co co-collectors can be viable alternatives for analysis of PGMs and gold using the fire assay method.